Once a Medicare beneficiary’s drug costs reach $2,100 in a calendar year, the beneficiary’s Part D plan takes over the entire remaining bill for the rest of that year — no coinsurance, no copay, nothing left to pay at the pharmacy counter. The Centers for Medicare & Medicaid Services confirmed the $2,100 threshold for 2026 in its Final CY 2026 Part D Redesign Program Instructions, an increase from the $2,000 cap that took effect the year before under the Inflation Reduction Act’s redesign of the Part D benefit. The number moves annually, tied to how fast prescription drug spending grows nationwide.
How Medicare Calculates What Counts Toward $2,100
CMS defines the annual out-of-pocket threshold using only what a beneficiary personally pays toward covered Part D drugs — the yearly deductible, copayments and coinsurance amounts all count, and the agency’s fact sheet on the redesigned benefit spells out that plan premiums and the cost of drugs not covered by a plan’s formulary do not count toward the cap no matter how much a beneficiary spends on them.
That distinction matters for someone paying a monthly Part D premium on top of drug costs, since a $50 monthly premium adds up to $600 a year that never moves the beneficiary closer to the cap, regardless of how expensive the premium is relative to income. Manufacturer discounts on brand-name drugs also count toward the total under the current benefit design, a detail that has shifted more than once since the Inflation Reduction Act began phasing in changes to Part D in 2023.
The redesign also tightened what counts as “creditable” drug coverage for beneficiaries who delay enrolling in Part D because they have coverage through a former employer. CMS’s final guidance raised the bar for that alternative coverage to pay at least 72 percent of a beneficiary’s prescription drug expenses, up from 60 percent under the prior standard, specifically because the richer $2,100-cap benefit made the old, lower bar too weak to qualify as an equivalent substitute without exposing a beneficiary to a late-enrollment penalty.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
The Three-Phase Benefit Design Behind the Cap
A beneficiary starts each calendar year in the deductible phase, paying 100 percent of drug costs out of pocket until reaching the $615 deductible CMS set for 2026. After the deductible, the beneficiary enters the initial coverage phase and pays 25 percent coinsurance on covered drugs, with the plan sponsor typically covering 65 to 75 percent of the remaining cost and, for negotiated drugs, the manufacturer and CMS splitting a smaller share through the Discount Program and the selected drug subsidy.
The initial coverage phase ends the moment a beneficiary’s out-of-pocket spending reaches $2,100 for the year, at which point the beneficiary moves into the catastrophic phase and pays nothing further for covered drugs through December 31. Plan sponsors continue paying roughly 60 percent of costs in the catastrophic phase, with CMS covering the rest through a reinsurance subsidy, meaning the government absorbs a larger share of spending the sicker or more expensive-to-treat a beneficiary becomes over the course of a year.
Why the Threshold Keeps Rising Each Year
The $2,100 figure for 2026 is not a fixed number written into the Inflation Reduction Act; the law set the original $2,000 cap for 2025 and instructed CMS to adjust it annually based on the percentage increase in average per-capita Part D drug spending, a formula the agency applied to arrive at $2,100 for the following year. That indexing means the cap will almost certainly rise again for 2027, though CMS has not yet published the exact figure and will not do so until its usual rate-announcement cycle later in the year — some beneficiaries manage the timing by spreading a large bill across months using the Medicare Prescription Payment Plan, a separate option that does not lower the $2,100 total but changes when it’s paid.
For a beneficiary managing a chronic condition with expensive specialty drugs, the cap functions as a hard ceiling on annual drug spending regardless of how many prescriptions they fill or how their condition changes over the year. For a beneficiary who rarely fills a prescription, the cap is largely irrelevant, since most people never come close to spending $2,100 out of pocket on drugs in a single year even before the redesign lowered the ceiling from where it stood a few years earlier.
The cap’s steady increase — from $2,000 in 2025 to $2,100 in 2026 — sits in tension with the program’s stated goal of protecting beneficiaries from catastrophic drug costs, since a rising ceiling means beneficiaries pay somewhat more before hitting full coverage even as the overall benefit remains far more generous than it was before the redesign began phasing in. Whether that upward drift continues at a similar pace or accelerates will depend largely on how fast the negotiated prices taking effect in 2027 change the per-capita spending figure CMS uses in its formula.
CMS has offered no public estimate of what the 2027 threshold will be, and any number reported before the agency’s own rate announcement should be treated as speculation rather than a settled figure. Beneficiaries planning around next year’s drug costs have only the mechanism — deductible, then coinsurance, then a hard stop — to rely on until the agency publishes an actual number.
This article was drafted with AI assistance and edited for accuracy.
More Financial Reading
